Recruiting

TECTONICAbbott Coronary IVL System for Calcified Coronary Arteries

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Experimental

Device
Who is being recruted

Arterial Occlusive Diseases+5

+ Arteriosclerosis

+ Cardiovascular Diseases

Over 18 Years
+52 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: April 2025
See protocol details

Summary

Principal SponsorAbbott Medical Devices
Study ContactRebecca MaslowMore contacts
Last updated: March 13, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2025

Actual date on which the first participant was enrolled.

This study is focused on evaluating a new medical device called the Abbott Coronary Intravascular Lithotripsy (IVL) System, designed to treat patients with severely calcified and narrowed coronary arteries. These arteries are crucial as they supply blood to the heart, and severe calcification can lead to significant health issues. The study aims to assess how safe and effective this device is in preparing these arteries for a stent, a small tube used to keep the artery open. The study involves 335 participants across various locations in the United States. This research is important as it could lead to improved treatments for patients with challenging coronary artery conditions. Participants in the study will undergo a procedure where the Abbott Coronary IVL System is used to treat their coronary arteries. This device uses a method similar to breaking up kidney stones, targeting the calcified areas to make it easier to place a stent. The study will collect data on the safety of the procedure and how well it works by comparing the outcomes to established goals from previous medical studies. By participating, individuals contribute to understanding whether this new approach could be a reliable option for many patients in the future. The study is conducted under strict regulations to ensure participant safety and is a step towards gaining approval for wider use of the device.

Official TitleTECTONIC CAD Intravascular Lithotripsy (IVL) IDE Study
NCT06885177
Principal SponsorAbbott Medical Devices
Study ContactRebecca MaslowMore contacts
Last updated: March 13, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

335 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Arterial Occlusive DiseasesArteriosclerosisCardiovascular DiseasesCoronary Artery DiseaseCoronary DiseaseHeart DiseasesVascular DiseasesMyocardial Ischemia

Criteria

17 inclusion criteria required to participate
The target lesion must be a single de novo coronary lesion that has not been previously treated with ANY interventional procedure.

Single de novo target lesion stenosis of protected left main coronary artery (LMCA), or left anterior descending artery (LAD), right coronary artery (RCA), left circumflex artery (LCX), or ramus intermedius (RI), or of their branches with: a. Stenosis of ≥70% and <100% or b. Stenosis ≥50% and <70% with evidence of ischemia via positive stress test, or fractional flow reserve (FFR) value ≤0.80, or RFR/iFR <0.89 (or any other non-hyperemic pressure index), or IVUS or OCT minimum lumen area ≤4.0 mm^2

The target vessel reference diameter must be ≥2.5 mm and ≤4.0 mm.

The lesion length must not exceed 36 mm. 4a) Tandem lesions are allowed and considered one lesion if they are <5 mm apart and as long as the total lesion length does not exceed 36 mm, except for distal lesions without planned treatment and that are in vessels ≤2.0 mm in diameter.

Show More Criteria

35 exclusion criteria prevent from participating
Unprotected LMCA diameter stenosis >30%.

Target lesion has a myocardial bridge.

Target vessel is excessively tortuous, defined as the presence of 2 or more bends >90 degrees or 3 or more bends >75 degrees.

Definite or possible thrombus in the target vessel.

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Participants will receive treatment with Abbott's Coronary IVL System followed by stenting.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 41 locations

Recruiting

HonorHealth

Scottsdale, United StatesOpen HonorHealth in Google Maps
Recruiting

Arkansas Heart Hospital

Little Rock, United States
Recruiting

Kaiser Permanente - San Francisco

San Francisco, United States
Recruiting

MedStar Washington Hospital Center

Washington D.C., United States
Recruiting
41 Study Centers